Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: A phase II trial of a platinum-free regimen

Lung Cancer

Volumn 48, Issue 3, 2005, Pages 409-413

  Reck, Martin ^a   Groth, Gesine ^a   Buchholz, Erika ^b   Goetz, Elif ^c   Gatzemeier, Ulrich ^a   Manegold, Christian ^b  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Thoraxklinik ^*  (Germany)

^c GLAXOSMITHKLINE   (Germany)

Author keywords

Etoposide; Extensive disease; First line therapy; Platinum free regimen; SCLC; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 18844403356     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.11.013     Document Type: Article

References (20)

1. M.J. Matthews, and P.R. Gordon Morphology of pulmonary and pleural malignancies M.J. Straus Lung cancer: clinical diagnosis and treatment 1977 Grune & Stratton New York 49 69
2. U. Lassen, K. Østerlind, M. Hansen, P. Dombernowsky, B. Bergman, and H.H. Hansen Long-term survival in small cell lung cancer: post-treatment characteristics in patients surviving 5-18 years - an analysis of 1714 consecutive patients J Clin Oncol 13 1995 1215 1220
3. M. Wolf, K. Havemann, R. Holle, C. Gropp, P. Drings, and K. Hans Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small cell lung cancer: a multicenter German randomised trial J Clin Oncol 5 1987 1880 1889
4. D.C. Ihde Chemotherapy in lung cancer M.C. Brain PP. Carbone Current therapy in haematology-oncology 3 3rd ed. 1988 BC Dekker Toronto 213 217
5. D.C. Ihde Chemotherapy of lung cancer N Engl J Med 327 1992 1434 1439
6. A. Ardizzoni, H. Hansen, P. Dombernowsky, T. Gamucci, S. Kaplan, and P. Postmus Topotecan, a new active drug in the second line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease J Clin Oncol 15 5 1997 2090 2096
7. J. von Pawel, A. Depierrre, and K. Hans Topotecan in small cell lung cancer after failure of first-line therapy: multicenter phase II study (abstract) Eur J Cancer 33 Suppl. 8 1997 229 (abstract 1038)
8. J.H. Schiller, K. Kim, P. Hutson, R. De Vore, J. Glick, and J. Stewart Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial J Clin Oncol 14 1996 2345 2352
9. J. von Pawel, J.H. Schiller, F.A. Shepherd, S.Z. Fields, J.P. Kleisbauer, and N.G. Chrysson Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer J Clin Oncol 17 2 1999 658 667
10. E. Jonsson, H. Frridborg, P. Nygren, and R. Larrson Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients Eur J Clin Pharmacol 54 1998 509 514
11. J.A. Bonner, and T.F. Kozelsky The significance of the sequence of administration of etoposide and topotecan Cancer Chemother Pharmacol 39 1996 109 112
12. C. Kollmannsberger, K. Mross, A. Jakob, L. Kanz, and C. Bokemeyer Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience Oncology 56 1999 1 12
13. C.M. Whitacre, E. Zborowska, N.H. Gordon, W. Mackay, and N.A. Berger Topotecan increases topoisomerase II levels and sensitivity to treatment with etoposide in schedule-dependent process Cancer Res 57 1997 1425 1428
14. E. Buchholz, P. Drings, U. Mayer, S. Weiser, and C. Manegold Lung cancer sequential administration of topotecan and etoposide in extensive small cell lung cancer: a phase I study Proc Am Soc Clin Oncol 19 2000 A2156
15. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
16. P. Bunn, and D. Carney Overview of chemotherapy for small cell lung cancer Semin Oncol 24 2 Suppl. 7 1997 69 74
17. R. Gervais, E. Quoix, J.L. Breton, K. Mattson, J. Wilson, and G. Ross Randomized phase II study of topotecan/cisplatin versus topotecan/etoposide in patients with untreated extensive disease small cell lung cancer Proc Am Soc Clin Oncol 20 2001 A1268
18. D. Mavroudis, G. Pavlakou, G. Blazoyiannakis, M. Veslemes, F. Apostolopoulou, and Ch. Kouroussis Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer J Clin Oncol 39 2003 71 76
19. T.S. Mok, H. Wong, B. Zee, K.H. Yu, T.W. Leung, and T.W. Lee A phase I/II trial of sequential administration of topotecan and oral etoposide in the treatment of patients with small cell lung carcinoma Cancer 95 2002 1511 1519
20. P. O'Neill, P.I. Clark, D. Smith, E. Marshall, K. Hannigan, and G. Ross A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small cell lung cancer Oncology 61 Suppl. 1 2001 25 29